The Questionable Ethics of Anisina – Part II

I have lost a lot of sleep this week about my prior post on the relationship between Novogen/Anisina (ASX : NRT) and the Kids’ Cancer Project. I received some fairly scathing emails from donors who are obviously very passionate about what the Kids’ Cancer Project represents and – if I am honest with you –…

Novogen’s “Comprehensive Science Review”

What a complete and utter farce. At the end of July, acting CEO Iain Ross informed that markets that he would be conducing a systematic review of Novogen’s (ASX : NRT) prospects, with the goal of a shareholder update by the 1st of September. Today, we received the promised progress update in the form of…

A Tale of Two Companies

I honestly can’t recall the moment I felt compelled to bastardise Dickens. I suspect that it has been a gradual accumulation of neural triggers, little seismic bursts of thought association that gradually – over thousands of words – build into a tsunami of recognition that eventually crushes the civilisation of the mind. Thought association. Hmmmm. Was it the…

Keeping the flame alive…

Today, once again, Novogen announced that it has filed a couple of patents. Not received a notice of allowance or won an opposition or anything of commercial significance, but you know, just paperwork. Well done to Andrew Heaton and the team for getting some cunning new technology put down on the page – and especially a…

The Incest of ASX Biopharma

It’s pretty hard to beat the Brits when it comes to situational comedy. As a dual-Australian/Canadian national educated in the UK, I suppose I have an intrinsic affinity for that dry, offhand style of humour. A few years ago, I stumbled across a brilliant comedy skit that visually captures precisely the fundamental reason why ASX biopharma is…

Novogen’s Graham Kelly : Jumped or Pushed?

Intriguing stuff – you no doubt know that today Dr. Graham Kelly, CEO of Novogen, resigned from the company. In a reasonably perfunctory statement, it has been announced that Dr. Kelly will “leave the Company to resume his work in non-oncology based early stage research.” Well, clearly, it would have to be non-oncology based research, because…